Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

@article{Shah2013HepatotoxicityOT,
  title={Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.},
  author={Rashmi R Shah and Joel Morganroth and Devron R Shah},
  journal={Drug safety},
  year={2013},
  volume={36 7},
  pages={491-503}
}
The introduction of small-molecule tyrosine kinase inhibitors (TKIs) in clinical oncology has transformed the treatment of certain forms of cancers. As of 31 March 2013, 18 such agents have been approved by the US Food and Drug Administration (FDA), 15 of these also by the European Medicines Agency (EMA), and a large number of others are in development or under regulatory review. Unexpectedly, however, their use has been found to be associated with serious toxic effects on a number of vital… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 93 references

Similar Papers

Loading similar papers…